Next-Generation Sequencing (Ngs) In Relapsed/Refractory Triple-Negative Breast Cancer (Tnbc) In Israel

1028 Background: Relapsed/metastatic TNBC is an aggressive form of the disease that typically responds initially to chemotherapy, but eventually progresses in the majority of patients (pts). We hypothesized that a comprehensive NGS assay (FoundationOne) could identify novel therapy targets not routinely interrogated in TNBC pts. Methods: Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to ≥ 50 ng of DNA extracted from 26 TNBC FFPE specimens and sequenced to high, uniform coverage. Genomic alterations (GA) including base substitutions, small indels, copy number alterations, and select gene fusions, were characterized and reported for each pt sample. Actionable GAs were defined as those identifying anti-cancer targeted therapies on the market or in registered clinical trials. Results: The 26 TNBC pts had a mean age of 49.6 yrs (range, 28-74). All 26 tumors were ER-/PR-/HER2- on routine slide-based testing. Samples used fo...